Roche (VTX:ROG) received a CHF 264 price target from equities researchers at Deutsche Bank in a research report issued to clients and investors on Tuesday. The firm currently has a “neutral” rating on the healthcare company’s stock. Deutsche Bank’s price target suggests a potential upside of 9.77% from the company’s current price.

Other research analysts also recently issued reports about the company. Jefferies Group set a CHF 290 target price on Roche and gave the stock a “buy” rating in a report on Thursday, September 21st. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the company a “buy” rating in a research note on Thursday, September 21st. Barclays set a CHF 295 price objective on Roche and gave the company a “buy” rating in a research note on Wednesday, September 13th. J P Morgan Chase & Co reissued a “buy” rating on shares of Roche in a research note on Monday, September 11th. Finally, Credit Suisse Group set a CHF 300 price objective on Roche and gave the company a “buy” rating in a research note on Monday, September 11th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of CHF 261.84.

Shares of Roche (ROG) traded down CHF 0.10 on Tuesday, reaching CHF 240.50. The company’s stock had a trading volume of 853,694 shares, compared to its average volume of 1,680,000. Roche has a 52-week low of CHF 220.50 and a 52-week high of CHF 273.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with's FREE daily email newsletter.